Commentary|Podcasts|October 14, 2026

Subcutaneous, On-Body Administration Opens Potential Door for At-Home Treatment in Multiple Myeloma

Fact checked by: Chris Ryan, Riley Kandel

Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discuss potential avenues for at-home administration in myeloma.

Welcome to OncLive On Air®!

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive On Air covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed how on-body subcutaneous administration methods could allow for select at-home administration of therapies for patients with multiple myeloma. Dr Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic and a clinical member of the Cancer Prevention, Control and Population Research Program at Case Comprehensive Cancer Center in Ohio. Dr Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Rochester, Minnesota.

In the final episode of a 3-part series, Drs Faiman and Ailawadhi explained how they are integrating on-body administration of isatuximab-irfc (Sarclisa Escena) for subcutaneous injection into clinical practice following its July 2026 FDA approval, and the pair also shared how this method could represent a strategy for at-home treatment within the United States in the future.

In the first episode, Drs Faiman and Ailawadhi detailed the transition to subcutaneous administration of anti-CD38 monoclonal antibodies in multiple myeloma management. And in the second episode, they broke down how patient-centric treatment methods are a key focus in myeloma research..`

_____

That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.


Related to this article